Baseline hemoglobin and liver function predict tolerability and overall survival of patients receiving radioembolization for chemotherapy-refractory metastatic colorectal cancer

Andrew S. Kennedy, David Ball, Steven J. Cohen, Michael Cohn, Douglas M. Coldwell, Alain Drooz, Edward Ehrenwald, Samir Kanani, Fred M. Moeslein, Charles W. Nutting, Samuel G. Putnam, Steven C. Rose, Michael Savin, Sabine Schirm, Navesh K. Sharma, Eric Wang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Patients with liver metastatic colorectal cancer (mCRC) often benefit from receiving 90Y-microsphere radioembolization (RE) administered via the hepatic arteries. Prior to delivery of liverdirected radiation, standard laboratory tests may assist in improving outcome by identifying correctable preradiation abnormalities. Methods: A database containing retrospective review of consecutively treated patients of mCRC from July 2002 to December 2011 at 11 US institutions was used. Data collected included background characteristics, prior chemotherapy, surgery/ablation, radiotherapy, vascular procedures, 90Y treatment, subsequent adverse events and survival. Kaplan-Meier estimates compared the survival of patients across lines of chemotherapy. The following values were obtained within 10 days prior to each RE treatment: haemoglobin (HGB), albumin, alkaline phosphatase (Alk phosph), aspartate aminotransferase (AST), alanine transaminase (ALT), total bilirubin and creatinine. Common Terminology Criteria Adverse Events (CTCAEs) 3.0 grade was assigned to each parameter and analysed for impact on survival by line of chemotherapy. Consensus Guidelines were used to categorize the parameter grades as either within or outside guidelines for treatment. Results: A total of 606 patients (370 male; 236 female) were studied with a median follow-up was 8.5 mo. (IQR 4.3-15.6) after RE. Fewer than 11% of patients were treated outside recommended RE guidelines, with albumin being the most common, 10.5% grade 2 (< 3-2.0 g/dL) at time of RE. All seven parameters showed statistically significant decreased median survivals with any grade > 0 (P < 0.001) across all lines of prior chemotherapy. Compared to grade 0, grade 2 albumin decreased overall survival 67%; for grade 2 total bilirubin a 63% drop occurred, and grade 1 HGB resulted in 66% lower median survival. Conclusions: Review of pre-RE laboratory parameters may aid in improving median survivals if correctable grade > 0 values are addressed prior to radiation delivery. HGB < 10 g/dL is a well-known negative factor in radiation response and is easily corrected. Improving other parameters is more challenging. These efforts are important in optimizing treatment response to liver radiotherapy.

Original languageEnglish (US)
Pages (from-to)70-80
Number of pages11
JournalJournal of Gastrointestinal Oncology
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Colorectal Neoplasms
Hemoglobins
Drug Therapy
Survival
Liver
Guidelines
Radiation
Albumins
Radiotherapy
Hepatic Artery
Kaplan-Meier Estimate
Therapeutics
Aspartate Aminotransferases
Alanine Transaminase
Microspheres
Bilirubin
Terminology
Alkaline Phosphatase
Blood Vessels
Creatinine

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology

Cite this

Kennedy, Andrew S. ; Ball, David ; Cohen, Steven J. ; Cohn, Michael ; Coldwell, Douglas M. ; Drooz, Alain ; Ehrenwald, Edward ; Kanani, Samir ; Moeslein, Fred M. ; Nutting, Charles W. ; Putnam, Samuel G. ; Rose, Steven C. ; Savin, Michael ; Schirm, Sabine ; Sharma, Navesh K. ; Wang, Eric. / Baseline hemoglobin and liver function predict tolerability and overall survival of patients receiving radioembolization for chemotherapy-refractory metastatic colorectal cancer. In: Journal of Gastrointestinal Oncology. 2017 ; Vol. 8, No. 1. pp. 70-80.
@article{4d8d0d535e534741b2b19b9a58f5827f,
title = "Baseline hemoglobin and liver function predict tolerability and overall survival of patients receiving radioembolization for chemotherapy-refractory metastatic colorectal cancer",
abstract = "Background: Patients with liver metastatic colorectal cancer (mCRC) often benefit from receiving 90Y-microsphere radioembolization (RE) administered via the hepatic arteries. Prior to delivery of liverdirected radiation, standard laboratory tests may assist in improving outcome by identifying correctable preradiation abnormalities. Methods: A database containing retrospective review of consecutively treated patients of mCRC from July 2002 to December 2011 at 11 US institutions was used. Data collected included background characteristics, prior chemotherapy, surgery/ablation, radiotherapy, vascular procedures, 90Y treatment, subsequent adverse events and survival. Kaplan-Meier estimates compared the survival of patients across lines of chemotherapy. The following values were obtained within 10 days prior to each RE treatment: haemoglobin (HGB), albumin, alkaline phosphatase (Alk phosph), aspartate aminotransferase (AST), alanine transaminase (ALT), total bilirubin and creatinine. Common Terminology Criteria Adverse Events (CTCAEs) 3.0 grade was assigned to each parameter and analysed for impact on survival by line of chemotherapy. Consensus Guidelines were used to categorize the parameter grades as either within or outside guidelines for treatment. Results: A total of 606 patients (370 male; 236 female) were studied with a median follow-up was 8.5 mo. (IQR 4.3-15.6) after RE. Fewer than 11{\%} of patients were treated outside recommended RE guidelines, with albumin being the most common, 10.5{\%} grade 2 (< 3-2.0 g/dL) at time of RE. All seven parameters showed statistically significant decreased median survivals with any grade > 0 (P < 0.001) across all lines of prior chemotherapy. Compared to grade 0, grade 2 albumin decreased overall survival 67{\%}; for grade 2 total bilirubin a 63{\%} drop occurred, and grade 1 HGB resulted in 66{\%} lower median survival. Conclusions: Review of pre-RE laboratory parameters may aid in improving median survivals if correctable grade > 0 values are addressed prior to radiation delivery. HGB < 10 g/dL is a well-known negative factor in radiation response and is easily corrected. Improving other parameters is more challenging. These efforts are important in optimizing treatment response to liver radiotherapy.",
author = "Kennedy, {Andrew S.} and David Ball and Cohen, {Steven J.} and Michael Cohn and Coldwell, {Douglas M.} and Alain Drooz and Edward Ehrenwald and Samir Kanani and Moeslein, {Fred M.} and Nutting, {Charles W.} and Putnam, {Samuel G.} and Rose, {Steven C.} and Michael Savin and Sabine Schirm and Sharma, {Navesh K.} and Eric Wang",
year = "2017",
month = "1",
day = "1",
doi = "10.21037/jgo.2017.01.03",
language = "English (US)",
volume = "8",
pages = "70--80",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "1",

}

Kennedy, AS, Ball, D, Cohen, SJ, Cohn, M, Coldwell, DM, Drooz, A, Ehrenwald, E, Kanani, S, Moeslein, FM, Nutting, CW, Putnam, SG, Rose, SC, Savin, M, Schirm, S, Sharma, NK & Wang, E 2017, 'Baseline hemoglobin and liver function predict tolerability and overall survival of patients receiving radioembolization for chemotherapy-refractory metastatic colorectal cancer', Journal of Gastrointestinal Oncology, vol. 8, no. 1, pp. 70-80. https://doi.org/10.21037/jgo.2017.01.03

Baseline hemoglobin and liver function predict tolerability and overall survival of patients receiving radioembolization for chemotherapy-refractory metastatic colorectal cancer. / Kennedy, Andrew S.; Ball, David; Cohen, Steven J.; Cohn, Michael; Coldwell, Douglas M.; Drooz, Alain; Ehrenwald, Edward; Kanani, Samir; Moeslein, Fred M.; Nutting, Charles W.; Putnam, Samuel G.; Rose, Steven C.; Savin, Michael; Schirm, Sabine; Sharma, Navesh K.; Wang, Eric.

In: Journal of Gastrointestinal Oncology, Vol. 8, No. 1, 01.01.2017, p. 70-80.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Baseline hemoglobin and liver function predict tolerability and overall survival of patients receiving radioembolization for chemotherapy-refractory metastatic colorectal cancer

AU - Kennedy, Andrew S.

AU - Ball, David

AU - Cohen, Steven J.

AU - Cohn, Michael

AU - Coldwell, Douglas M.

AU - Drooz, Alain

AU - Ehrenwald, Edward

AU - Kanani, Samir

AU - Moeslein, Fred M.

AU - Nutting, Charles W.

AU - Putnam, Samuel G.

AU - Rose, Steven C.

AU - Savin, Michael

AU - Schirm, Sabine

AU - Sharma, Navesh K.

AU - Wang, Eric

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Patients with liver metastatic colorectal cancer (mCRC) often benefit from receiving 90Y-microsphere radioembolization (RE) administered via the hepatic arteries. Prior to delivery of liverdirected radiation, standard laboratory tests may assist in improving outcome by identifying correctable preradiation abnormalities. Methods: A database containing retrospective review of consecutively treated patients of mCRC from July 2002 to December 2011 at 11 US institutions was used. Data collected included background characteristics, prior chemotherapy, surgery/ablation, radiotherapy, vascular procedures, 90Y treatment, subsequent adverse events and survival. Kaplan-Meier estimates compared the survival of patients across lines of chemotherapy. The following values were obtained within 10 days prior to each RE treatment: haemoglobin (HGB), albumin, alkaline phosphatase (Alk phosph), aspartate aminotransferase (AST), alanine transaminase (ALT), total bilirubin and creatinine. Common Terminology Criteria Adverse Events (CTCAEs) 3.0 grade was assigned to each parameter and analysed for impact on survival by line of chemotherapy. Consensus Guidelines were used to categorize the parameter grades as either within or outside guidelines for treatment. Results: A total of 606 patients (370 male; 236 female) were studied with a median follow-up was 8.5 mo. (IQR 4.3-15.6) after RE. Fewer than 11% of patients were treated outside recommended RE guidelines, with albumin being the most common, 10.5% grade 2 (< 3-2.0 g/dL) at time of RE. All seven parameters showed statistically significant decreased median survivals with any grade > 0 (P < 0.001) across all lines of prior chemotherapy. Compared to grade 0, grade 2 albumin decreased overall survival 67%; for grade 2 total bilirubin a 63% drop occurred, and grade 1 HGB resulted in 66% lower median survival. Conclusions: Review of pre-RE laboratory parameters may aid in improving median survivals if correctable grade > 0 values are addressed prior to radiation delivery. HGB < 10 g/dL is a well-known negative factor in radiation response and is easily corrected. Improving other parameters is more challenging. These efforts are important in optimizing treatment response to liver radiotherapy.

AB - Background: Patients with liver metastatic colorectal cancer (mCRC) often benefit from receiving 90Y-microsphere radioembolization (RE) administered via the hepatic arteries. Prior to delivery of liverdirected radiation, standard laboratory tests may assist in improving outcome by identifying correctable preradiation abnormalities. Methods: A database containing retrospective review of consecutively treated patients of mCRC from July 2002 to December 2011 at 11 US institutions was used. Data collected included background characteristics, prior chemotherapy, surgery/ablation, radiotherapy, vascular procedures, 90Y treatment, subsequent adverse events and survival. Kaplan-Meier estimates compared the survival of patients across lines of chemotherapy. The following values were obtained within 10 days prior to each RE treatment: haemoglobin (HGB), albumin, alkaline phosphatase (Alk phosph), aspartate aminotransferase (AST), alanine transaminase (ALT), total bilirubin and creatinine. Common Terminology Criteria Adverse Events (CTCAEs) 3.0 grade was assigned to each parameter and analysed for impact on survival by line of chemotherapy. Consensus Guidelines were used to categorize the parameter grades as either within or outside guidelines for treatment. Results: A total of 606 patients (370 male; 236 female) were studied with a median follow-up was 8.5 mo. (IQR 4.3-15.6) after RE. Fewer than 11% of patients were treated outside recommended RE guidelines, with albumin being the most common, 10.5% grade 2 (< 3-2.0 g/dL) at time of RE. All seven parameters showed statistically significant decreased median survivals with any grade > 0 (P < 0.001) across all lines of prior chemotherapy. Compared to grade 0, grade 2 albumin decreased overall survival 67%; for grade 2 total bilirubin a 63% drop occurred, and grade 1 HGB resulted in 66% lower median survival. Conclusions: Review of pre-RE laboratory parameters may aid in improving median survivals if correctable grade > 0 values are addressed prior to radiation delivery. HGB < 10 g/dL is a well-known negative factor in radiation response and is easily corrected. Improving other parameters is more challenging. These efforts are important in optimizing treatment response to liver radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85014390505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014390505&partnerID=8YFLogxK

U2 - 10.21037/jgo.2017.01.03

DO - 10.21037/jgo.2017.01.03

M3 - Article

C2 - 28280611

AN - SCOPUS:85014390505

VL - 8

SP - 70

EP - 80

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 1

ER -